|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differing coping mechanisms, stress level and anorectal physiology in patients with functional constipation显示文摘AIM: To investigate coping mechanisms, constipation symptoms and anorectal physiology in 80 constipated subjects and 18 controls.METHODS: Constipation was diagnosed by Rome Ⅱ criteria.Coping ability and anxiety/depression were assessed by validated questionnaires. Transit time and balloon distension test were performed.RESULTS: 34.5% patients were classified as slow transit type of constipation. The total colonic transit time (56 h vs 10 h, P<0.0001) and rectal sensation including urge sensation (79 mL vs 63 mL, P = 0.019) and maximum tolerable volume (110 mL vs95 mL, P = 0.03) differed in patients and controls. Constipated subjects had significantly higher anxiety and depression scores and lower SF-36 scores in all categories. They also demonstrated higher scores of'monitoring' coping strategy (14+6 vs9+3, P = 0.001),which correlated with the rectal distension sensation (P = 0.005), urge sensation (P=0.002), and maximum tolerable volume (P = 0.035). The less use of blunting strategy predicted slow transit constipation in both univariate (P = 0.01) and multivariate analysis (P = 0.03).CONCLUSION: Defective or ineffective use of coping strategies may be an important etiology in functional constipation and subsequently reflected in abnormal anorectal physiology. | Annie OO Chan Cecilia Cheng Wai Mo Hui Wayne HC Hu Nina YH Wong KF Lam Wai Man Wong Kam Chuen Lai Shiu Kum Lam Benjamin CY Wong | 2005 | World Journal of Gastroenterology2005，11，34： | 92 |
| 2 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 3 | Assessment of visual function in chronic progressive external ohthalmoplegia 显示文摘 | Yu Wai Man CY Smith T | 2006 | Eye2006，20，5： | 1 |
| 4 | Sport-related ankle injuries attending an accident and emergency department显示文摘 | Fong DT Man CY Yung PSH | 2008 | Injury2008，39，： | 1 |
| 5 | Visual outcome after open globe injury:a eom-parison of two prognostic models-the Ocular Trauma Score and the Classification and Regression Tree 显示文摘 | Man CY Steel D | 2010 | Eye(Lond)2010，24，： | 1 |
| 6 | Vitexin and isovitexin from the leaves of Ficus dehoidea with in - vivo ct - glucosidase inhibition 显示文摘 | Choo CY Sulong NY Man F | 2012 | J Ethnopharmacol2012，142，3： | 1 |
| 7 | Comparison of oral prednisolone/paracetamol and oral indomethacin/para- cetamol combination therapy in the treatment of acute goutlike arthritis : a double -blind, randomized, controlled trial 显示文摘 | Man CY Cheung IT Cameron PA | 2007 | Ann EmergMed2007，49，5： | 1 |
| 8 | Sport-related ankle injuries attending an accident and emergency department显示文摘 | Fong DTP Man CY Yung PSH | | 0，，10： | 1 |
| 9 | Extraocular Muscles have Fundamentally Distinct Properties that Make them Selectively Vulnerable to Certain Disorders显示文摘 | YU WAI MAN CY CHINNERY PF GRIFFITHS PG | 2005 | Neuromuscul Disord(S0960-8966)2005，15，1： | 1 |
| 10 | Intramyocellular lipidaccumulation is associated with permanent relocation exvivo and in vitro of fatty acid translocase (FAT)/CD36 inobese patients显示文摘 | Aguer C Mercier J Man CY | 2010 | Diabetologia2010，53，6： | 1 |
| 11 | The tumour-suppressor genes lgl and dlg regulate basal protein targeting in Drosophila neuroblasts 显示文摘 | Manning L Albertson R | 2000 | Nature2000，408，6812： | 1 |
| 12 | Intramyocellular lipid accumulation is associated with permanent relocation ex vivo and in vitro of fatty acid translocase(FAT)/CD36 in obese patients显示文摘 | Aguer C Mercier J Man CY | | 0，，： | 1 |
| 13 | Nursing students' clinical judgment in high- fidelity simulation based learning: a quasi- experimental study显示文摘 | Yuan HB Williams BA Man CY | 2014 | J Nurs Educ Prac2014，4，5： | 1 |
| 14 | Intramyocellular lipid accumulation is associated with permanent relocation ex vivo and in vitro of fatty acid translocase(FAT)/CD36 in obese patients显示文摘 | Aguer C Mercier J Man CY | | 0，，： | 1 |
| 15 | Visual outcome after open globe injury: a comparison of two prognostic models--the Ocular Trauma Score and the Classification and Regression Tree显示文摘 | Man CY Steel D | 2010 | Eye (Lond)2010，24，1： | 1 |
| 16 | Intramyocellular lipid accumula- tion is associated with permanent relocation ex vivo and in vitro of fatty acid translocase ( fat)/cd36 in obese patients 显示文摘 | Aguer C Mercier J Man CY | 2010 | Diabetologia2010，53，6： | 1 |
| 17 | Agreement between initial and final diagnosis of first seizures,epilepsy and non-epileptic events:a prospective study显示文摘 | Leung H Man CY Hui AC | | 0，，10： | 1 |
| 18 | Solid breast nodules: use of sonography to distinguish between benign and imalignant lesions显示文摘 | Stavros AT Thick man D Rapp CY e t a l | 1995 | Radiology1995，196，1： | 1 |
| 19 | Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders显示文摘 | Yu Wai Man CY Chinnery PF Griffiths PG | 2005 | Neuromuscul Disord2005，15，1： | 1 |
| 20 | ND4 mutation in transitional cell carcinoma: Does mitochondrial mutation occur before tumorigenesis ? 显示文摘 | Tzen CY Man BL Wu TY | 2007 | Mitochondrion2007，17，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员